MGI Tech and Dasa: A New Era in Healthcare Collaboration
MGI Tech Co., Ltd. ("MGI"), recognized for its dedication to advancing life sciences, has joined forces with Dasa, the leading medical diagnostics firm in Latin America. This strategic partnership aims to make next-generation genomic technologies more accessible for patients in Brazil, while also improving the accuracy of diagnosing various health issues, including cancers and rare diseases.
Establishing a robust framework for genomic testing is vital for personalized medicine. This collaboration will empower healthcare providers to offer more effective and tailored treatment plans for patients. By utilizing MGI's cutting-edge genetic sequencing technology, Dasa's healthcare professionals will be equipped to provide diagnoses that are both timely and precise.
Boosting Genomic Capabilities Across Brazil
Since 2019, MGI has made significant strides in Brazil, operating in over 100 countries. Earlier this year, they introduced a Customer Experience Center (CEC) to enhance the infrastructure for genomic sequencing and scientific innovation in the region. Their technology plays a crucial role in Brazil's largest genomic sequencing initiative, Genomas Brasil, further fortifying the country's healthcare system.
Carlos Carpio, MGI's Senior Commercial Director for Latin America and General Manager for Brazil, expressed his excitement about this collaboration. He commented, "We look forward to leveraging MGI's technology alongside Dasa's established diagnostic expertise. Together, we can increase service capacity for a growing number of patients with high-quality genetic sample processing, fueling advancements in healthcare. This partnership will play a significant role in personalizing medicine efforts in Brazil, ultimately enhancing health outcomes for everyone."
Advancing Precision Medicine
For Gustavo Riedel, Dasa's Director of Genomics LATAM, this partnership signifies an important move toward improved healthcare in Brazil. He remarked, "Blending our specialized health services with MGI's genomic technologies ensures better access to precision medicine for Brazilian patients, which leads to more defined and effective treatment options for a variety of illnesses."
This collaboration has already initiated the rollout of MGI’s sequencers and automation products throughout Dasa’s network of laboratories. The addition of cutting-edge equipment, including the DNBSEQ-T7 high-throughput sequencer and MGISP-100 and MGISP-960 automation systems, is designed to streamline laboratory workflows. This advancement will help reduce processing times and costs, while also boosting laboratory efficiency.
Transforming Healthcare in Brazil
The partnership between MGI and Dasa is poised to revolutionize the Brazilian healthcare market by integrating advanced genomic sequencing technologies. In an environment where state-of-the-art medical technologies have often been financially inaccessible, this initiative is a major step forward. It will democratize access to genomic testing, allowing a larger segment of the Brazilian population to benefit from advancements in precision medicine.
Riedel elaborated, "With this innovative platform, we have seen significant improvements in quality, efficiency, and process standardization. Our aim is to make healthcare more accessible to the public by delivering timely results at increasingly affordable prices."
About MGI Tech
Based in Shenzhen, MGI Tech Co. Ltd. is dedicated to pioneering technologies that advance life sciences. Their focus includes the research, development, production, and sale of sequencing instruments, reagents, and related products that support life science research, agriculture, precision medicine, and broader healthcare initiatives. As a premier manufacturer of clinical high-throughput gene sequencers, MGI is committed to developing next-generation life science tools that will shape the future of healthcare.
About Dasa
Dasa stands as Brazil's largest integrated healthcare network, positively impacting over 23 million lives each year through its innovative technology and proactive care approach. With a workforce that exceeds 50,000 employees and a network of 250,000 partner physicians, Dasa is dedicated to delivering healthcare solutions that address community needs across various points in the care continuum.
The focus on comprehensive care drives Dasa to embrace preventative, predictive, and personalized healthcare. They integrate services across diagnostic medicine, hospitals, genomics, and telemedicine, ensuring both accessibility and quality for patients throughout Brazil.
Dasa's digital healthcare management platform, Nav, simplifies the patient journey while providing streamlined services for healthcare professionals. The company's commitment to integrated and innovative corporate health solutions through Dasa Empresas helps meet the diverse needs of its patients effectively.
Frequently Asked Questions
What does the partnership between MGI Tech and Dasa aim to achieve?
The partnership seeks to improve access to genomic technologies and enhance the precision of diagnosing cancers and rare diseases in Brazil.
How will the collaboration benefit patients in Brazil?
This collaboration enables more timely and accurate diagnoses through advanced genetic testing, which enhances treatment options for patients.
What technologies will be implemented through this alliance?
MGI’s sequencers and automation products, such as the DNBSEQ-T7 and MGISP automation systems, will optimize laboratory workflows and efficiency.
Who is MGI Tech and what are their goals?
MGI Tech Co., Ltd. is focused on advancing life sciences through innovative technologies, particularly in genomic testing and precision medicine.
What is Dasa's mission?
Dasa is committed to offering comprehensive healthcare solutions that integrate a range of services, ensuring high-quality care for over 23 million individuals each year.
